BD Receives Order from Canada Government for 37 Million Injection Devices to Support Vaccination Program


Publish date: Jun. 02, 2020

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued a statement following the receipt of a large pandemic order from the Canadian government for 37 million needles and syringes to support Canada’s planning for a vaccination effort for COVID-19. The statement can be attributed to Greg Miziolek, president of BD - Canada:


“BD is the largest manufacturer of injection devices in the world, producing billions of syringes and needles annually through our global manufacturing network. BD’s commitment to produce 37 million vaccine injection devices to support Canada in planning for a COVID-19 vaccination campaign is the latest effort in the company’s multifaceted global response to this virus.


“In Canada, BD is committed to supporting our health care systems across the country in response to the COVID-19 pandemic by supplying critical technologies such as diagnostic tools, injection devices and other essential medical technologies used in the treatment of COVID-19 patients. BD applauds the provinces, territories and the federal government for their proactive and coordinated approach in planning for future COVID-19 needs. We thank the government for their leadership, and we look forward to continuing to work with all levels of government in Canada, as we partner together to respond to the COVID-19 pandemic.”


About BD


BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.


Kristen Cardillo

201 847 5657

Monique N. Dolecki

201 847 5378